Stavovi i saveti vezani za izbor farmaceutskih oblika lekova za lečenje respiratornih infekcija kod dece

  • Sandra Cvijić Univerzitet u Beogradu – Farmaceutski fakultet, Katedra za farmaceutsku tehnologiju i kozmetologiju
  • Dušica Mirković Vojnomedicinska akademija, Institut za farmaciju
  • Danina Krajišnik Univerzitet u Beogradu – Farmaceutski fakultet, Katedra za farmaceutsku tehnologiju i kozmetologiju
DOI: https://doi.org/10.5937/arhfarm72-37643
Ključne reči: farmaceutski oblici lekova za decu, lekovi prilagođeni pedijatrijskom uzrastu, izrada magistralnih lekova, aplikatori za primenu/doziranje lekova, respiratorne infekcije

Sažetak


Terapija respiratornih infekcija kod dece zahteva posebnu pažnju, jer ovu populaciju čini specifična i izuzetno heterogena grupa pacijenata. Veoma je važno odabrati odgovarajući farmaceutski oblik leka, u skladu sa karakteristikama aktivne supstance, kao i stanjem i uzrastom deteta. U praksi se, u terapiji respiratornih infekcija kod dece, najviše koriste preparati za oralnu primenu, za parenteralnu primenu i za inhalaciju. Međutim, veliki broj lekova nije dostupan u odgovarajućem farmaceutskom obliku i/ili jačini za pedijatrijski uzrast, usled čega je česta neodobrena upotreba lekova. Prilikom izbora/izrade preparata za decu potrebno je pažljivo razmotriti i sastav preparata (bezbednost pomoćnih supstanci), kao i izbor aplikatora, u skladu sa uzrastom deteta. U ovom radu je dat prikaz farmaceutskih oblika lekova koji se koriste u terapiji respiratornih infekcija kod dece, njihovih prednosti i izvesnih nedostataka. Navedeni su različiti primeri farmaceutskih preparata, uz poseban osvrt na izbor aplikatora za primenu/doziranje lekova. Takođe, diskutovane su specifičnosti pedijatrijske populacije koje utiču na izbor odgovarajuće formulacije leka prilagođene uzrastu deteta.

Reference

Ghimire P, Gachhadar R, Piya N, Shrestha K, Shrestha K. Prevalence and factors associated with acute respiratory infection among under-five children in selected tertiary hospitals of Kathmandu Valley. PLoS One. 2022;17(4): e0265933.

Tazinya AA, Halle-Ekane GE, Mbuagbaw LT, Abanda M, Atashili J, Obama MT. Risk factors for acute respiratory infections in children under five years attending the Bamenda Regional Hospital in Cameroon. BMC Pulm Med. 2018;18(1):7.

Bamel VV, Shahani SR, Mohanty NC. Study of drug utilization and antimicrobial prescription pattern of indoor paediatrics cases in tertiary care hospital. Int J Basic Clin Pharmacol. 2018;7:98-102.

European Medical Agency (EMA) [Internet]. Reflection paper: Formulations of choice for the paediatric population; 2006. [cited 2022 Apr 25]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-formulations-choice-paediatric-population_en.pdf.

Ivanovska V, Rademaker CM, van Dijk L, Mantel-Teeuwisse AK. Pediatric drug formulations: a review of challenges and progress. Pediatrics. 2014;34(2):361-72.

British National Formulary for children 2021-2022. London: British Medical Association, Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group, 2021.

Guy’s and St. Thomas’, King’s College and University Lewisham Hospitals Paediatric Formulary. 9th ed. Tomlin S, Kirk E, editors. Guy’s & St Thomas’ NHS Foundation Trust, 2012.

Hoon D, Taylor MT, Kapadia P, Gerhard T, Strom BL, Horton DB. Trends in off-label drug use in ambulatory settings: 2006-2015. Pediatrics. 2019;144(4):e20190896.

Jong GW, Eland IA, Sturkenboom MC, van den Anker JN, Strickerf BH. Unlicensed and off-label prescription of respiratory drugs to children. Eur Respir J. 2004;23(2):310-3.

Badar V, Parulekar V, Garate P. A prescription pattern study of respiratory tract infections in paediatric indoor patients in a tertiary care teaching hospital - a prospective observational study. Asian J Pharm Clin Res. 2018;11(7):251-4.

Bandela A, Rathod S, Mullukuntla M, Guduru VK, Puchchakayala G. An assessment of antibiotic drugs utilization pattern in paediatric population. In J Phar Pract. 2019:12(4). doi: 10.5530/ijopp.12.4.53.

Alili-Idrizi E, Malaj L, Dauti M. Spectrum of infectious diseases and antibiotic usage in a paediatric outpatient department. Eur Sci J. 2013:.9(30):364-70.

World Health Organization [Internet]. WHO model prescribing information: drugs used in bacterial infections; 2001 [cited 2022 Apr 25]. Available from: https://apps.who.int/iris/handle/10665/42372.

World Health Organization [Internet] Development of paediatric medicines: points to consider in formulation. Annex 5, WHO Technical Report Series 970; 2012 [cited 2022 Apr 25]. Available from: https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/trs970/annex5trs-970.pdf?sfvrsn=699cdb68_8&download=true.

Ivanovska V, Leufkens HG, Rademaker CM, Zisovska E, Pijnenburg MW, van Dijk L, et al. Are age-appropriate antibiotic formulations missing from the WHO list of essential medicines for children? A comparison study. Arch Dis Child. 2017:102(4):352-56.

World Health Organization [Internet]. WHO Model List of Essential Medicines for Children - 8th list; 2021 [cited 2022 Apr 25]. Available from: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.03.

World Health Organization [Internet]. WHO model formulary for children; 2010 [cited 2022 Apr 25]. Available from: https://apps.who.int/iris/handle/10665/44309.

Faizin C, Kusumawati W, Habib I. Evaluation of antibiotics prescription in the pediatric patient. JMMR. 2019:8(1):32-9.

Batchelor HK, Marriott JF. Formulations for children: problems and solutions. Br J Clin Pharmacol. 2015:79(3):405-18.

Medicines and Medical Devices Agency of Serbia [Internet]. [cited 2022 Apr 25]. Available from: https://www.alims.gov.rs/english/.

The electronic medicines compendium (emc) [Internet]. [cited 2022 Apr 20]. Available from: https://www.medicines.org.uk/emc/.

DailyMed [Internet]. [cited 2022 Apr 20]. Available from: https://dailymed.nlm.nih.gov/dailymed/.

Food and Drug Administration (FDA) [Internet]. Guidance for Industry Size of Beads in Drug Products Labeled for Sprinkle; 2012 [cited 2022 Apr 25]. Available from: https://www.fda.gov/files/drugs/published/Size-of-Beads-in-Drug-Products-Labeled-for-Sprinkle-Rev.1.pdf.

World Health Organization [Internet]. Revised WHO classification and treatment of childhood pneumonia at health facilities: EVIDENCE SUMMARIES; 2014 [cited 2022 Apr 25. Available from: https://apps.who.int/iris/bitstream/handle/10665/137319/9789241507813_eng.pdf.

Galande AD, Khurana NA, Mutalik S. Pediatric dosage forms—challenges and recent developments: A critical review. J App Pharm Sci. 2020;10(7):155-66.

Rashi G, Rampal M, Sujit P, Nikhl B. A review on medicated lollipops. Res J Pharmacognosy and Phytochem. 2021;13(1):33-8.

European Medicines Agency [Internet]. Committee for Medicinal Products for Human Use (CHMP). Guideline on pharmaceutical development of medicines for paediatric use; 2013 [cited 2022 Apr 20]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf.

Walsh J, Bickmann D, Breitkreutz J, Chariot-Goulet M, European Paediatric Formulation Initiative (EuPFI). Delivery devices for the administration of paediatric formulations: overview of current practice, challenges and recent developments. Int J Pharm. 2011:415(1-2):221-31.

Wolfe TR, Braude DA. Intranasal medication delivery for children: a brief review and update. Pediatrics. 2010;126(3):532-7.

Bar-Shalom D, Rose K, editors. Pediatric formulations: a roadmap. New York: Springer; 2014. 273-8 p.

Borland ML, Bergesio R, Pascoe EM, Turner S, Woodger S. Intranasal fentanyl is an equivalent analgesic to oral morphine in paediatric burns patients for dressing changes: a randomised double blind crossover study. Burns. 2005;31(7):831-7.

Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ. 2000;321(7253):83-6.

Ramvikas M, Arumugam M, Chakrabarti SR, Jaganathan KS. Nasal vaccine delivery. In: Skwarczynski M, Tóth I, editors. Micro and Nanotechnology in Vaccine Development. Amsterdam: William Andrew Publishing; 2017; p. 279-301.

Goldman RD. Intranasal drug delivery for children with acute illness. Curr Drug Ther. 2006;1(1):127-30.

Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013;3(1):42-62.

O’Brien F, Clapham D, Krysiak K, Batchelor H, Field P, Caivano G, et al. Making medicines baby size: The challenges in bridging the formulation gap in neonatal medicine. Int J Mol Sci. 2019;20(11):2688.

European Pharmacopoeia, 10th edition. Supplement 10.3. Strasbourg: Council of Europe, 2021.

Rouaz K, Chiclana-Rodríguez B, Nardi-Ricart A, Suñé-Pou M, Mercadé-Frutos D, Suñé-Negre JM, et al. Excipients in the paediatric population: A review. Pharmaceutics. 2021;13(3):387.

Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’ (SANTE-2017-11668) EMA/CHMP [Internet]. 2019 [cited 2022 Apr 20]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human_en.pdf.

Cutrera R, Baraldi E, Indinnimeo L, Miraglia Del Giudice M, Piacentini G, Scaglione F, et al. Management of acute respiratory diseases in the pediatric population: the role of oral corticosteroids. Ital J Pediatr. 2017;43(1):31.

Muchão FP, Filho LV. Advances in inhalation therapy in pediatrics. J Pediatr. (Rio J). 2010;86(5):367-76.

Wilmott RW. Hoods are effective for aerosol delivery in RSV bronchiolitis. J Pediatr. 2005;147(5):A3.

Heitman T, Day AJ, Bassani AS. Pediatric compounding pharmacy: taking on the responsibility of providing quality customized prescriptions. Children. 2019;6(5):66.

Jew RK, Soo-Hoo W, Erush SC, Amiri E, American Society of Health-System Pharmacists. Extemporaneous formulations: Extemporaneous formulations for pediatric, geriatric, and special needs patients. Bethesda, MD : American Society of Health-System Pharmacists, Inc.; 2016. xi-xiii p.

Barker C, Turner M, Sharland M. Prescribing medicines for children: From drug development to practical administration. London, UK: Pharmaceutical Press; 2019. 163-9 p.

Gudeman J, Jozwiakowski, M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R&D. 2013;13(1):1-8.

Mullarkey, T. Pharmacy compounding of high-risk level products and patient safety. Am J Health Syst Pharm. 2009;66(17 Suppl 5):S4-13.

Scheepers HPA, Handlos VN, Walser S, Schutjens MDB, Neef, C. Impact of the Council of Europe Resolution on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients. Eur J Hosp Pharm. 2017;24(4):218-23.

The United States Pharmacopoeia 42, The National Formulary 37, Rockville, MD: United States Pharmacopoeial Convention, 2019.

Minghetti P, Pantano D, Gennari CGM, Casiraghi A. Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe. Health Policy. 2014;117(3):328-33.

Resolution CM/Res(2016)1 on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients. Committee of Ministers, Council of Europe, 2016.

PIC/S Guide to Good Practices for the Preparation of Medicinal Products in Healthcare Establishments, Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-Operation Scheme [Internet]. 2014 [cited 2022 Apr 20]. Available from: https://picscheme.org/docview/3443.

Allen LV. Gentamicin 40 mg/mL for Inhalation. US Pharm. 2015;40(7):57-8.

Objavljeno
2022/06/29
Broj časopisa
Vol. 72 Br. Notebook 3 (2022): Arhiv za farmaciju
Rubrika
Pregledni (Revijalni) rad
Autori koji objavljuju u ovom časopisu pristaju na sledeće uslove:

  1. Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.

  2. Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.

  3. Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).